文献速递中医内科中药与中成药合理使用

冠心丹参方通过上调雌激素受体β改善心肌缺血再灌注损伤后左室重构

Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β.
PubMed 文献 · Front Pharmacol · 2017-11-01

本研究探讨冠心丹参方(GXDSF)对心肌缺血再灌注损伤诱导的左室重构(MIRI-LVR)的作用及机制。结果显示GXDSF可改善心脏功能、降低心肌损伤标志物和纤维化指标,其作用可能与上调ERβ并经PI3K/Akt信号通路相关。

要点

  • GXDSF改善MIRI-LVR模型的心脏收缩功能并降低心肌损伤标志物。
  • GXDSF减轻心肌纤维化,降低胶原I/III、α-SMA及纤维化百分比。
  • ERβ拮抗剂PHTPP可部分逆转GXDSF的保护作用,提示ERβ为关键靶点。

核心结论

  • 冠心丹参方通过上调ERβ并经PI3K/Akt信号通路,对心肌缺血再灌注损伤诱导的左室重构发挥防治潜力。

研究设计与样本

  • 采用MIRI-LVR动物模型,通过血流动力学、超声心动图、生化指标和组织病理学评估GXDSF效应,并用TCMSP数据库预测靶点,以蛋白质印迹和免疫荧光双染验证。

主要发现

  • GXDSF治疗组+dp/dt和LVSP较模型组显著升高,LVEF和LVFS较模型组增加。
  • GXDSF治疗组AST、LDH和CK-MB较模型组显著降低。
  • GXDSF治疗组胶原I和III、α-SMA及左室纤维化百分比不同程度降低,胶原III/I比值升高。
  • TCMSP预测和蛋白质印迹提示ERβ可能为GXDSF主要靶点。
  • ERβ选择性拮抗剂PHTPP可抑制GXDSF诱导的ERβ表达及PI3K和Akt磷酸化,并部分逆转GXDSF对+dp/dt、LVEF、LVFS、LDH、CK-MB、α-SMA和心肌纤维化的改善作用。

临床怎么用

  • 对于心肌缺血再灌注损伤后左室重构患者,可考虑冠心丹参方作为潜在治疗选择,但其临床疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Guanxin Danshen formulation (GXDSF) is a traditional Chinese herbal recipe recorded in the Chinese Pharmacopeia since 1995 edition, which consists of Salviae miltiorrhizae Radix et Rhizoma, Notoginseng Radix et Rhizoma and Dalbergiae odoriferae Lignum. Our previous research suggested GXDSF had positive effect on cardiovascular disease. Therefore, the aim of this study was to elucidate the effects of GXDSF on myocardial ischemia reperfusion injury-induced left ventricular remodelling (MIRI-LVR). Methods: The effects of GXDSF on cardiac function were detected by haemodynamics and echocardiograms. The effects of GXDSF on biochemical parameters (AST, LDH and CK-MB) were analyzed. Histopathologic examinations were performed to evaluate the effect of GXDSF on cardiac structure. In addition, the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to predict the main target of GXDSF. Target validation was conducted by using western blots and immunofluorescent double staining assays. Results: We found that +dp/dt and LVSP were significantly elevated in the GXDSF-treated groups compared with the MIRI-LVR model group. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) were increased in the GXDSF-treated groups compared with the model group. All biochemical parameters (AST, LDH and CK-MB) were considerably decreased in the GXDSF-treated groups compared with the model group. Fibrosis parameters (collagen I and III, α-SMA, and left ventricular fibrosis percentage) were decreased to different degrees in the GXDSF-treated groups compared with the model group, and the collagen III/I ratio was elevated by the same treatments. TCMSP database prediction and western blot results indicated that estrogen receptor β (ERβ) could be the main target of GXDSF. PHTPP, a selective antagonist of ERβ, could inhibit the expression of ERβ and the phosphorylation of PI3K and Akt in myocardial tissue induced by GXDSF, and partly normalize the improving effects of GXDSF on +dp/dt, LVEF, LVFS, LDH, CK-MB, α-SMA and myocardial fibrosis. Conclusion: Collectively, GXDSF showed therapeutic potential for use in the prevention and treatment of myocardial ischemia reperfusion injury-induced ventricular remodeling by upregulating ERβ via PI3K/Akt signaling. Moreover, these findings may be valuable in understand the mechanism of disease and provide a potential therapy of MIRI-IVR.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Deng X, Xing X, Sun G, et al. Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Receptor β. Front Pharmacol. 2017. PMID: 29163163. doi:10.3389/fphar.2017.00777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。